



ISSN:2394-2371  
CODEN (USA):IJPTIL

REVIEW PAPER

## Novel in vitro methods for cancer research using 3D tumour models: A Review

Nilesh Kumar Saini<sup>1</sup>, Sunita Jangid<sup>1</sup>, Yogesh Kanwadiya<sup>1</sup>, Khushi Tanwer<sup>1</sup>, Dushyant Soni<sup>1</sup>, Madhusudan Periwal<sup>1</sup>, Harshit Ranjan Srivastava<sup>1</sup>, Divyansh Prakash Gupta<sup>1\*</sup>

<sup>1</sup>Amity Institute of Pharmacy, Amity University Rajasthan, Jaipur, Rajasthan, India

\*Corresponding Author: Divyansh Prakash Gupta

### ABSTRACT

Each year, 10 million people die from cancer, a multifactorial disease. It is challenging to create single targeted approaches due to the intra- and inter-heterogeneity of malignant tumours. But it seems that they are frequently less suitable than the three-dimensional (3D) cell culture approach for simulating the biological behaviour of tumour cells, particularly the mechanisms causing therapeutic escape and drug resistance. The last 20 years have seen the development of immunotherapy as a cutting-edge and effective cancer treatment method. Preclinical tests for novel medicines are frequently unreliable, predictive indicators are frequently still poorly characterised, and mechanisms of action are sometimes still uncertain. Models used in vivo during research and conventional bidimensional culture systems may not accurately reflect the analysis of tumor/immune system interaction in this context, it still plays a crucial role. To connect in IVIVC systems, tumour cell cultures in three dimensions have been produced. Interesting characteristics of the interaction between tumour cells and cells from the innate and adaptive immune systems may also be reflected by 3D preparations. Here we evaluate in vitro models of cancer/immune cell interaction and suggest that new technologies may aid in the development of novel therapies, the identification of biologicals with potential clinical relevance, and the identification of patients who may benefit from immunotherapy.

**Keywords:** - *Cancer immunotherapy, 3D cell culture models, tumor-immune interactions, drug resistance mechanisms, preclinical cancer modeling, IVIVC systems*

### INTRODUCTION

According to the World Health Organisation (2011), cancer was one of the leading causes of mortality globally in 2007, accounting for around 7.9 million fatalities. A solid cancer is a tumour mass that is hypoxic at the centre and heavier than the surrounding tissue, such as those found in the breast, colon, stomach, lung, and liver. Cancer is marked at the molecular level by the cancer cells' escape from normal growth regulation and their acquisition of an invasive potential. Along with this, a supporting

#### \*CORRESPONDING AUTHOR

**Divyansh Prakash Gupta**

Amity Institute of Pharmacy, Amity University Rajasthan,  
Jaipur, Rajasthan, India

E.Mail: [dg184701@gmail.com](mailto:dg184701@gmail.com)

Article Published: July – September 2025

#### CITE THIS ARTICLE AS

Gupta D.P. et al. *Novel in vitro methods for cancer research using 3D tumour models: A Review. Int. J. Pharm. Technol. Biotechnol.* 2025; 12(3):01-14.

stroma that has a larger vasculature is formed. It takes beneficial chemical interactions between cancer cells and the tumour stroma for malignancies to spread and invade. These come together to form a solid tumor-specific clinically observable invasive tumour mass


[1, 2].

Epithelial cancer cells that form cancer foci are the primary cause of most malignancies (carcinomas). They engage in dynamic interactions with the extracellular matrix (ECM), which is a source of glycosylated proteins, and the stroma surrounding them, which is made up primarily of fibroblasts and endothelial cells (ECs, which line blood vessels). For growth and development, epithelial-stromal interactions are essential. For instance, Calmels et al. (1995) found that without a blood supply, the cancer mass cannot expand over 200 m in circumference [3, 4]. Hypoxia-inducible factor (HIF1) is increased in cancer cells when there is a lack of oxygen. The angiogenic factor cascade proteins, such as vascular endothelial growth factor (VEGF), whose transcription is regulated in a temporally different manner, are afterwards promoted by this.

In order to create new capillaries and provide the cancer cells those are multiplying with enough nutrients and oxygen, the latter draws ECs towards the cancer cells. The hypoxic centre of the cancer mass feeds the cycle of growth and vascularization. Inflammatory cells (macrophages, neutrophils, and mast cells) are also present in the tumour stroma. Since they produce pro-angiogenic factors (like VEGF and basic fibroblast growth factor [bFGF]) on demand at specific locations, these promote tumour aggressiveness through stimulation of angiogenesis. Integrins, an ECM protein involved in cell-cell and cell-matrix interactions, are frequently the driving force behind cancer cell invasion. Through cascades like the focal adhesion kinase signalling pathway or the mitogen-activated protein kinase pathway, which regulate the invasive and metastatic progression of malignant cells, they play a crucial role in metastasis [2, 3, 9].

In controlling tumour growth and progression, the relationship between cancer cells and the immune system is crucial. Indeed, the ability to resist immune-mediated destruction and tumor-promoting inflammation are true cancer hallmarks. Studies on clinical samples have powerfully validated findings from experiments, and examination of innate and adaptive immune system infiltration of human tumours has revealed highly significant predictive connections. Most significantly, immunotherapies are now commonly used to treat individuals with malignancies with various histological origins [10, 11]. For approximately 20 years, several monoclonal antibodies (mAbs) have been employed frequently in the management of cancer [12]. They were frequently created to stop the binding of growth factor-induced receptors expressed by tumour cells that promote their proliferation. However, an immune cell-mediated process like their clinical effectiveness is frequently shown to be mediated via phagocytosis and antibody-dependent cell cytotoxicity. Therapeutic mAbs may, in fact, play a crucial role in the cytotoxicity of target cells caused by lymphocytes or myeloid cells that contain activating Fc receptors, depending on their affinity and isotype. Whether it is preferable to kill target cells or only prevent them from interacting with certain ligands without killing them is a key question in mAb-mediated

immunotherapy, especially in light of cutting-edge medicines that recognise markers released by immune cells.




**Fig.1.** Exhibiting the main supportive non-cancer stromal cells, key protein families, and tumour bulk with stroma.

In the latter scenario, it would be advised to employ mAbs that bind inhibitory Fc receptors. Isotype is becoming increasingly important for the success or failure of reagents recognising the same target molecule in light of the present uncertainty surrounding the mechanisms of action of some therapeutic mAbs. On the basis of this backdrop, chemicals with varying affinities and capacities to bind the Fc receptors expressed by effector cells are continuously being created [11, 13]. Furthermore, advanced clinical experimentation is currently being conducted on bispecific mAbs that specifically target defined effector functions to tumour cells [14]. The most significant development is the successful testing and application of therapeutic mAbs that recognise immunological checkpoints in clinical settings over the past ten years. Their creation is justified by the theory that they are intended to prevent the physiological inhibition of adaptive T cell responses caused by interaction between antigen-specific T cells' activation markers and their ligands, which are expressed by cancer cells or antigen-presenting cells, respectively. Numerous cancers have shown benefit from releasing the brakes on antitumor responses. However, the mechanisms of action are still unclear, and markers that accurately predict clinical responsiveness have yet to be found. Anti-CD47 mAbs have also been employed to encourage macrophage phagocytosis of tumour cells along similar lines [15, 16]. Additionally, in the last 20 years, adoptive cancer immunotherapies have been created. They are founded on giving autologous cells to patients after in vitro expansion and culture. Current adoptive therapies typically rely on the use of T cells from patients transduced with genes encoding conventional or enhanced-avidity HLA-restricted T-cell receptors recognising tumor-associated antigens, or chimeric HLA-unrestricted antigen receptors (CAR) recognising surface molecules expressed in high levels by cancer cells. Clinical trials are currently being

conducted that also focus on solid malignancies, despite the fact that these technologies are mostly employed to treat haematological malignancies [12, 17]. As a result of these discoveries, a sizable number of novel biologicals and methods for cancer immunotherapy are being created and tested in clinical studies. [18]. There is currently an unheard-of explosion of information and applications in this field of study, which necessitates the development of preclinical assays and the identification of individuals who may benefit from treatment [20].

### 3D Models

Connections between individual cells and the extracellular matrix cannot be fully understood using culture in two dimensions that are based on the development and proliferation of a monolayer of cells. With the help of 3D culture models, cells become polarised between a basal and an apical pole, which results in changes to proteins and the genome. When a tumour is present, the extracellular matrix and the tissue microenvironment are both changed. This manifests as a change in the distribution of nutrients, oxygen, and metabolites as well as in cell growth and communication. All of the 2D models, however, fall short of accurately simulating *in vivo* interactions because they cannot simultaneously evaluate each of these crucial characteristics. Compared to 2D cultures, greater immuno-modulatory properties than 2D models, such as melanoma-derived spheroids, proliferative, and activating properties [21]. Immune checkpoint molecules express differently *in vivo* compared to 2D culture models. This makes it crucial to adopt 3D cell culture models that more faithfully represent the TME. Spheroids and organoids are two terms used to describe 3D cell culture models. Technical developments allowed for the complexification of cocultures in both of these models, improving the TME representation [22,20]. Tumors on chip and bioprinting do, in fact, combine technology and 3D culture to mimic fluid dynamics or tumour cell architecture. However, the semantic distinction between spheroid and organoids is hazy and appears to be based on the author's personal preference [23]. When the terms tumor-organoid or spheroid are used in cancer studies, the term "organoid" is frequently used to describe healthy primary cells and tissue biopsy cultures. While tumour organoids are used for complex structures involving multiple cell types and mimicking tissue architecture, spheroid is used for simple three-dimensional structures [21, 23]. When biopsies are used without any digesting step, the line separating the two words is still unclear. When cell lines, digested biopsies, and non-digested biopsies are cultivated in non-adherent conditions to produce 3D models, the term "tumor-spheroid" can be employed. To preserve the tissue architecture and tissue variety when undigested or lysed tissue is grown in an extracellular matrix, tumour organoids should be utilised. As a result, we categorised 3D models into a gradient of complexity, with cellular composition at its core, as seen in **Figure 2**.




**Fig 2.** 3D culture model (3D culture models are represented based on how complicated they are. Spheroids made from a single cell line to extremely complex models made from patient tissue or tumours improved with a microfluidic chip are all examples of 3D culture models. Tumour biopsy and 2D culture are employed as complexity references. Cell line-derived models and patient-derived models can be distinguished in 3D cultures. Tissue mincing, or tissue mincing and enzymatic digestion, are both necessary for patient-derived 3D models before the culture. Notably, bioprinting can be used to create the majority of models that call for cell type-dependent structures in multiple cell types and can be used directly on microfluidic chips.)

### The Current State of Modelling Human Tumor-Immune System Interactions

Experimental animal models used *in vivo* have provided important information that has been used to produce therapeutic mAbs and novel immunotherapy techniques. The availability of enough quantities of newly isolated tumour or immune cells as well as autologous immune/tumor cell systems has proven to be a challenge in *in vitro* research using human cells, which have been more challenging. In addition, while having a comparable histological origin, developing established tumour cell lines from clinical specimens is still a difficult task, and the inherent variability of human tumours should not be overlooked [23,24]. However, conventional *in vitro* models have consistently shown to be of the utmost significance in human immunology, and particularly in tumour immunology. Standard bidimensional cultures have made it possible to grow tumor-infiltrating lymphocytes, create T cell clones that specifically target tumours, and keep track of how well therapeutic antitumor vaccinations are working. <sup>51</sup>Cr release assays have served as the gold standard for identifying human tumour associated antigens [25]. For the evaluation of adaptive T cell responses, flow-cytometry techniques based on the detection of cells expressing T-cell receptors that recognise antigenic peptides restricted by defined HLA determinants, such as multimers, are frequently supplemented by the analysis of intracellular cytokine expression upon antigenic triggering [26,27]. In conjunction with these methods, so-called Elispot tests are routinely used to pinpoint individual cells that, in response to an antigenic stimulus, produce a

particular cytokine. For patients receiving immunotherapy, a combination of these methods is presently used to track their antigen-specific T cell responses (**Figure 3**).




**Fig.3** T lymphocyte/tumor interactions are now studied in vitro using assays. Currently, a number of recognised tests are used to evaluate the antitumor capabilities of human immune cells ex vitro.

### Why Novel Tumour Immune System Interaction Models Are Vital?

According to in vitro research, macrophages and T and NK cells can effectively elicit antitumor actions under specific test settings. The clinical success of immunological checkpoints targeted therapy, however, also indirectly suggests that cytotoxic tumour infiltrating T cells are commonly dysfunctional in vivo [28]. Additionally, immune-histochemical research suggests that solid tumours most frequently lack NK cell infiltration that can be seen. More importantly, macrophage infiltration of solid tumours is typically linked to a poor prognosis, except for a few cases, such as colorectal cancer (CRC) [29, 30]. Immune cell functional profiles that differ between in vivo and in vitro have sparked investigation into the factors that lead to. Alternatively activated macrophages, regulatory Hypoxia and adenosine receptor triggering, as well as the production of ligands for immunological checkpoints, have all been demonstrated to be immunosuppressive mechanisms at work in the tumour microenvironment [31, 32]. The responsiveness of lymphocytes may be significantly impacted by oxygen levels, according to earlier research. More recently, a significant number of studies seem to suggest that hypoxia and specific metabolic conditions present in tumour tissues may act as a unifying background for a number of previously noted immunosuppressive mechanisms and significantly reduce the potential efficacy of anticancer immune responses. Hypoxia has been found to promote immunological tolerance by attracting Tregs. It is intriguing that metabolic changes in tumour tissues have been linked to PD-1 immune checkpoint expression [33]. The battle for glucose between tumour cells and T-cell receptor-triggered, antigen-specific T cells, both of which are characterised by aerobic glycolysis, seems to be a significant issue. Additionally, increased glycolysis has been linked to pro-tumor M2 macrophage

activation, and hypoxia has been linked to the emergence of myeloid derived suppressor cells within the tumour microenvironment (Figure 4).



**Fig.4.** Interactions between the tumour and immune cells due to metabolic changes in the tumour microenvironment. Hypoxia and aerobic glycolysis, among other metabolic characteristics, are present in the in vivo tumour microenvironment, where they cause competition between tumour and immune cells for glucose and other resources and the formation of lactic acid.

**Table.1. 2D versus 3D Cell Culture Methods**

Characteristics	2D	3D
<b>Cell morphology</b>	Loss of epithelial cell polarity and altered cell shape, which is typically flat and elongated.	Cells continue to proliferate in 3D aggregates while maintaining their native structure and polarisation.
<b>Gene expression</b>	Typically, genes associated to cell adhesion, proliferation, and survival are altered	Representation of gene expression patterns accurately
<b>Cell proliferation and differentiation</b>	Poor cell differentiation and excessively high proliferation are both present in cells.	Cells are well differentiated; proliferation is realistic depending on 3D matrix interactions
<b>Cell interactions</b>	Deprived of cell–cell and cell–ECM interactions, no cell niches are created	Cell junctions are common and allow cell communication
<b>Tumoral heterogeneity</b>	Basic; all cells receive the same amount of nutrients; inaccurate replication of the TME	Better approximation and representation of the TME; nutrients are not equally supplied
<b>Response to stimuli</b>	Inaccurate representation of mechanical and biochemical cues	Cells grow in a 3D environment and receive stimuli from all directions that properly represent in vivo stimuli
<b>Reproducibility</b>	Highly replicable	Difficult to replicate some conditions
<b>Analysis and quantification</b>	Easy interpretation of results; better long-term cultures	Difficult to analyze data, especially with multiple cell types or when in spheroid/organoid conformation
<b>Cost</b>	Cheaper for large-scale studies	More complex and expensive techniques

**Three-dimensional modelling of interactions between the immune system and human tumours**

In an effort to address the high attrition rate in the creation of novel anticancer drugs, numerous tridimensional culture models have been developed in the past. Identifying the metabolic processes, gene expression patterns, and sensitivity to treatment resistance of cancer cells. These results have motivated the development of innovative high throughput drug screening tools, which are now being applied in pharmacological research. Early research involved creating multicellular spheroids by preventing tumour cells from adhering to plastic cell culture surfaces. Later technologies based on microfluidics, scaffolds, and hanging drops were developed with success [23, 34]. Spheroid size control has made it possible to create structures with controlled levels of hypoxia, and perfused bioreactors have proven effective at producing tissue-like structures from well-established human tumour cell lines [35]. In this context, it is also remarkable that human cancer cells with the ability to initiate tumours, also known as tumour initiating cells (TIC) or cancer stem cells (CSC), are often characterised by the capacity to produce spheres that are able to slowly replicate with asymmetric divisions in tumours with a variety of histological origins, such as the colon, breast, and CNS.

Models with increased complexity are constantly being created with the goal of incorporating more tumour microenvironment elements that have been shown to be important for clinical outcome and the emergence of treatment resistance. The scientific community is also becoming more and more interested in the physical characteristics of tumour tissues and the potential for recreating them accurately in vitro. Microfluidics models have been created in particular to address drug sensitivity and cancer cell dispersion, tumour lymphatic vessel interaction, and homing of tumour cells to specific metastatic niches. It's interesting to note that the earliest 3D culture models were initially created to study the immune response to solid tumour allografts [34, 36]. In light of the foregoing, it is surprising that only a small number of research have examined how 3D culture of tumour cells affects those cells' susceptibility to the actions of lymphocyte effectors [37]. Early research revealed that breakdown of this architecture was a crucial prerequisite for the full elicitation of antitumor cytotoxicity and that cytokine-activated lymphocytes had difficulty targeting tumour cells cultivated in three dimensions. The effector activities of T cells are significantly compromised when target cells are arranged in 3D structures, as we and others have recently discovered [38].


Numerous mechanisms have been put forth. Ineffective antigen presentation, according to Dangles-Marie et al., may be caused by tumour target cells' reduced expression of the heat shock protein-70 [39]. Following culture in spheroids, we found that cells from well-established melanoma cell lines may down-regulate expression of HLA and melanoma differentiation antigens. It's interesting to note that clinical melanoma specimens with hypoxic areas showed lower expression of the Melan-A/MART-1 differentiation antigen [32, 34]. On the other hand, lactic acid production increases in 3D-cultured cells compared to 2D-cultured cells. Notably, the levels of lactic acid produced under these circumstances are

sufficient to significantly reduce the activation of antigen-specific cytotoxic T lymphocyte (CTL) clones' effector functions, establishing a crucial connection between the typical metabolic abnormalities of tumour cells and T cell functional impairment.

Natural killer (NK) cell cytotoxicity against targets cultivated in tridimensional structures has also been described, as has the study of NK lymphocyte infiltration in scaffold-free and 3D Matrigel-based models. Increased HLA-E expression by tumour cells has been specifically linked to tumour cells' resistance to NK lymphocyte-mediated cytotoxicity in 3D glioma models. It has been demonstrated that NK and Treg contact with breast cancer cells in 3D leads to an increase in the creation of inflammatory cells that are pro-tumor significant and CCL4-attractive. There aren't many studies looking into B-cell tumour cell interaction in 3D designs, despite the fact that they might be important in the cancer microenvironment. The analysis of tumor/lymphocyte interaction has most recently also been proposed using models based on microfluidic technology [35]. Lymphocytes have been the subject of several works on tridimensional modelling. But human cancers also frequently contain macrophages and other myeloid cells. By cytokine treatment, monocyte/macrophage lineage cells from murine and, M1 macrophages with anticancer potential or M2 macrophages can be polarised into human tissues. Which have a pro-angiogenic functional profile and have been proven to be more tumor-supportive [36]. It is crucial to keep in mind that the M1/M2 polarisation concept is a convenient oversimplification of a process that is actually best described as a continuum. However, it has been demonstrated that tridimensional tumour spheroids can significantly alter the differentiation and functional profiles of monocytes and macrophages [34, 39].

It has been demonstrated that a coculture of squamous cell carcinoma cells with human and murine macrophages in 3D architectures, in the presence or absence of fibroblasts, promotes the polarisation of these cells towards an M2 functional profile and induces metalloproteases (MMP) production, favouring tumour invasiveness as related to increased extracellular matrix degradation. Similar findings were also made in trials using cell lines from bladder, breast, thyroid, and hepatic cancers. In each of these instances, changes in the chemokine secretome in 3D cultures with tumour cells and macrophages, whether fibroblasts were present or not, were consistently seen. Using microfluidic devices, it has been demonstrated that M2 macrophages preferentially bind to NSCLC cells grown in aggregates, hence promoting their migration and EMT. In this work, macrophages cultivated under various settings that may have been connected to intermediate polarisation stages were evaluated side by side. TNF and TGF-1 released by macrophages have most recently also been found to promote tumour cell motility in a 3D extracellular matrix [36, 37]. Importantly, however, it has been demonstrated in 3D cultures, including microfluidic models, that the lactic acid produced by tumour cells inhibits the antigen presentation and differentiation capacity of DCs (**Figure 5**). According to these findings, tridimensional

models could be utilised to analyse, under controlled circumstances, the interactions that occur in vivo between tumour cells and cells of the monocyte/macrophage/dendritic cell lineages.



**Fig.5.** Immune cell effector actions target tumour cell spheroids. (Verification of the impact of tridimensional culture on a range of immune cell functions has been done using tumour cell spheroids produced by various techniques. T-cell clones that recognise antigens linked to melanoma have been coculture with the cancer cells (panel A). Similar testing has been done on CAR-transduced cells for adoptive therapies. Additionally evaluated were the roles of cells from the monocyte/macrophage lineage in phagocytosis and antigen presentation. Furthermore, using target cells cultured as spheroids, NK cells have been studied in relation to antibody-dependent cell cytotoxicity.)

### Conclusion:

In vitro models will never be able to capture the immense complexity of cancer progression in vivo, which is all too clear. However, they might offer the chance to put cutting-edge therapies and fundamental science hypotheses to the test under very strict controls. Due to the significant advancements of the last two decades, there have been an unprecedented number of preclinical and clinical studies on tumour immunobiology and immunotherapy. Innovative in vitro technologies must be developed in order to evaluate the efficacy of novel treatments. Surprisingly, it will be necessary to test these treatments' potential toxicity. In this field, on target/off target reactivity, tumour lysis syndromes, and cytokine release do pose serious issues that call for the development of suitable in vitro models. The investigation of tumour genomes and the tumour microenvironment, on the other hand, is challenging the present tumour classification and staging criteria, which are typically used to select patients for conventional therapy procedures. An additional motivator for the development of novel culture technologies may be the growing desire for personalised treatments. The in vitro modelling of tumour immune-system interactions has a promising future, as may be easily predicted given this background.

**References:**

1. Vesely, M. D.; Kershaw, M. H.; Schreiber, R. D.; Smyth, M. J. Natural innate and adaptive immunity to cancer. *Annu. Rev. Immunol.* 2011, 29, 235– 71, DOI: 10.1146/annurev-immunol-031210-101324 , [PubMed],
2. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. *Nature* 2008, 454 (7203), 436– 444, DOI: 10.1038/nature07205 [CAS],
3. Schreiber, R. D.; Old, L. J.; Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. *Science* 2011, 331 (6024), 1565– 1570, DOI: 10.1126/science.1203486, Google Scholar
4. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. *Cell* 2011, 144 (5), 646– 674, DOI: 10.1016/j.cell.2011.02.013 .
5. Fridman, W. H.; Pages, F.; Sautes-Fridman, C.; Galon, J. The immune contexture in human tumours: impact on clinical outcome. *Nat. Rev. Cancer* 2012, 12 (4), 298– 306, DOI: 10.1038/nrc3245 .
6. Topalian, S. L.; Drake, C. G.; Pardoll, D. M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. *Curr. Opin. Immunol.* 2012, 24 (2), 207– 12, DOI: 10.1016/j.coi.2011.12.009
7. Weiner, G. J. Building better monoclonal antibody-based therapeutics. *Nat. Rev. Cancer* 2015, 15 (6), 361– 70, DOI: 10.1038/nrc3930
8. Golay, J.; Introna, M. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. *Arch. Biochem. Biophys.* 2012, 526 (2), 146– 53, DOI: 10.1016/j.abb.2012.02.011 [Crossref], Google Scholar
9. Furness, A. J.; Vargas, F. A.; Peggs, K. S.; Quezada, S. A. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. *Trends Immunol.* 2014, 35 (7), 290– 8, DOI: 10.1016/j.it.2014.05.002 [Crossref], [PubMed], [CAS], Google Scholar
10. Topalian, S. L.; Taube, J. M.; Anders, R. A.; Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. *Nat. Rev. Cancer* 2016, 16 (5), 275– 87, DOI: 10.1038/nrc.2016.36 [Crossref], [PubMed], [CAS], Google Scholar
11. Golay, J.; Da Roit, F.; Bologna, L.; Ferrara, C.; Leusen, J. H.; Rambaldi, A.; Klein, C.; Introna, M. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. *Blood* 2013, 122 (20), 3482– 91, DOI: 10.1182/blood-2013-05-504043 [Crossref], Google Scholar
12. Mossner, E.; Brunker, P.; Moser, S.; Puntener, U.; Schmidt, C.; Herter, S.; Grau, R.; Gerdes, C.; Nopora, A.; van Puijenbroek, E.; Ferrara, C.; Sondermann, P.; Jager, C.; Strein, P.; Fertig, G.; Friess, T.; Schull, C.; Bauer, S.; Dal Porto, J.; Del Nagro, C.; Dabbagh, K.; Dyer, M. J.; Poppema, S.; Klein, C.; Umana, P. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. *Blood* 2010, 115 (22), 4393– 402, DOI: 10.1182/blood-2009-06-225979 [Crossref], Google Scholar
13. Klein, C.; Schaefer, W.; Regula, J. T. The use of CrossMAb technology for the generation of bi- and multispecific antibodies. *MAbs* 2016, 8 (6), 1010– 20, DOI: 10.1080/19420862.2016.1197457 [Crossref], [PubMed], [CAS], Google Scholar
14. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. *Nat. Rev. Cancer* 2012, 12 (4), 252– 64, DOI: 10.1038/nrc3239 [Crossref], [PubMed], [CAS], Google Scholar

15. Page, D. B.; Postow, M. A.; Callahan, M. K.; Allison, J. P.; Wolchok, J. D. Immune modulation in cancer with antibodies. *Annu. Rev. Med.* 2014, 65, 185– 202, DOI: 10.1146/annurev-med-092012-112807 [Crossref], [PubMed], [CAS], Google Scholar
16. McCracken, M. N.; Cha, A. C.; Weissman, I. L. Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals. *Clin. Cancer Res.* 2015, 21 (16), 3597– 601, DOI: 10.1158/1078-0432.CCR-14-2520 [Crossref], [PubMed], [CAS], Google Scholar
17. Weiskopf, K.; Jahchan, N. S.; Schnorr, P. J.; Cristea, S.; Ring, A. M.; Maute, R. L.; Volkmer, A. K.; Volkmer, J. P.; Liu, J.; Lim, J. S.; Yang, D.; Seitz, G.; Nguyen, T.; Wu, D.; Jude, K.; Guerston, H.; Barkal, A.; Trapani, F.; George, J.; Poirier, J. T.; Gardner, E. E.; Miles, L. A.; de Stanchina, E.; Lofgren, S. M.; Vogel, H.; Winslow, M. M.; Dive, C.; Thomas, R. K.; Rudin, C. M.; van de Rijn, M.; Majeti, R.; Garcia, K. C.; Weissman, I. L.; Sage, J. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. *J. Clin. Invest.* 2016, 126 (7), 2610– 20, DOI: 10.1172/JCI81603 [Crossref], Google Scholar
18. Fesnak, A. D.; June, C. H.; Levine, B. L. Engineered T cells: the promise and challenges of cancer immunotherapy. *Nat. Rev. Cancer* 2016, 16 (9), 566– 81, DOI: 10.1038/nrc.2016.97 [Crossref], [PubMed], [CAS], Google Scholar
19. Chambers, C. A.; Kuhns, M. S.; Egen, J. G.; Allison, J. P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. *Annu. Rev. Immunol.* 2001, 19, 565– 94, DOI: 10.1146/annurev.immunol.19.1.565 [Crossref], [PubMed], [CAS], Google Scholar
20. Cerottini, J. C.; Nordin, A. A.; Brunner, K. T. Specific in vitro cytotoxicity of thymus-derived lymphocytes sensitized to alloantigens. *Nature* 1970, 228 (5278), 1308– 9, DOI: 10.1038/2281308a0 [Crossref], Google Scholar
21. Coulie, P. G.; Van den Eynde, B. J.; van der Bruggen, P.; Boon, T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. *Nat. Rev. Cancer* 2014, 14 (2), 135– 46, DOI: 10.1038/nrc3670 [Crossref], [PubMed], [CAS], Google Scholar
22. Van der Bruggen, P.; Traversari, C.; Chomez, P.; Lurquin, C.; DePlaen, E.; Van den Eynde, B.; Knuth, A.; Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. *Science* 1991, 254 (5038), 1643– 1647, DOI: 10.1126/science.1840703 [Crossref], [PubMed], [CAS], Google Scholar
23. Topalian, S. L.; Muul, L. M.; Solomon, D.; Rosenberg, S. A. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. *J. Immunol. Methods* 1987, 102 (1), 127– 41, DOI: 10.1016/S0022-1759(87)80018-2 [Crossref], [PubMed], [CAS], Google Scholar
24. Adamina, M.; Rosenthal, R.; Weber, W. P.; Frey, D. M.; Viehl, C. T.; Bolli, M.; Huegli, R. W.; Jacob, A. L.; Heberer, M.; Oertli, D.; Marti, W.; Spagnoli, G. C.; Zajac, P. Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma. *Mol. Ther.* 2010, 18 (3), 651– 659, DOI: 10.1038/mt.2009.275 [Crossref], [PubMed], [CAS], Google Scholar
25. Janetzki, S.; Britten, C. M.; Team, M. C. The role of the reporting framework MIATA within current efforts to advance immune monitoring. *J. Immunol Methods* 2014, 409, 6– 8, DOI: 10.1016/j.jim.2014.05.003 [Crossref], [PubMed], [CAS], Google Scholar
26. Tseng, D.; Volkmer, J. P.; Willingham, S. B.; Contreras-Trujillo, H.; Fathman, J. W.; Fernhoff, N. B.; Seita, J.; Inlay, M. A.; Weiskopf, K.; Miyanishi, M.; Weissman, I. L. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. *Proc. Natl. Acad. Sci. U. S. A.* 2013, 110 (27), 11103– 8, DOI: 10.1073/pnas.1305569110 [Crossref], [PubMed], [CAS], Google Scholar

27. Zippelius, A.; Batard, P.; Rubio-Godoy, V.; Bioley, G.; Lienard, D.; Lejeune, F.; Rimoldi, D.; Guillaume, P.; Meidenbauer, N.; Mackensen, A.; Rufer, N.; Lubenow, N.; Speiser, D.; Cerottini, J. C.; Romero, P.; Pittet, M. J. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. *Cancer Res.* 2004, 64 (8), 2865– 2873, DOI: 10.1158/0008-5472.CAN-03-3066 [Crossref], Google Scholar
28. Korman, A. J.; Peggs, K. S.; Allison, J. P. Checkpoint blockade in cancer immunotherapy. *Adv. Immunol.* 2006, 90, 297– 339, DOI: 10.1016/S0065-2776(06)90008-X [Crossref], [PubMed], [CAS], Google Scholar
29. Pietra, G.; Manzini, C.; Rivara, S.; Vitale, M.; Cantoni, C.; Petretto, A.; Balsamo, M.; Conte, R.; Benelli, R.; Minghelli, S.; Solari, N.; Gualco, M.; Queirolo, P.; Moretta, L.; Mingari, M. C. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. *Cancer Res.* 2012, 72 (6), 1407– 15, DOI: 10.1158/0008-5472.CAN-11-2544 [Crossref], Google Scholar
30. Sconocchia, G.; Arriga, R.; Tornillo, L.; Terracciano, L.; Ferrone, S.; Spagnoli, G. C. Melanoma cells inhibit NK cell functions. *Cancer Res.* 2012, 72 (20), 5428– 5429, DOI: 10.1158/0008-5472.CAN-12-1181 [Crossref], Google Scholar
31. Condeelis, J.; Pollard, J. W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. *Cell* 2006, 124 (2), 263– 266, DOI: 10.1016/j.cell.2006.01.007 [Crossref], [PubMed], [CAS], Google Scholar
32. Mantovani, A.; Sozzani, S.; Locati, M.; Allavena, P.; Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. *Trends Immunol.* 2002, 23 (11), 549– 555, DOI: 10.1016/S1471-4906(02)02302-5 [Crossref], [PubMed], [CAS], Google Scholar
33. Colombo, M. P.; Piconese, S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. *Nat. Rev. Cancer* 2007, 7 (11), 880– 7, DOI: 10.1038/nrc2250 [Crossref], [PubMed], [CAS], Google Scholar
34. Gabrilovich, D. I.; Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. *Nat. Rev. Immunol.* 2009, 9 (3), 162– 74, DOI: 10.1038/nri2506 [Crossref], [PubMed], [CAS], Google Scholar
35. Palazon, A.; Aragones, J.; Morales-Kastresana, A.; de Landazuri, M. O.; Melero, I. Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. *Clin. Cancer Res.* 2012, 18 (5), 1207– 1213, DOI: 10.1158/1078-0432.CCR-11-1591 [Crossref], [PubMed], [CAS], Google Scholar
36. Sitkovsky, M.; Lukashev, D. Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. *Nat. Rev. Immunol.* 2005, 5 (9), 712– 21, DOI: 10.1038/nri1685 [Crossref], [PubMed], [CAS], Google Scholar
37. Atkuri, K. R.; Herzenberg, L. A.; Herzenberg, L. A. Culturing at atmospheric oxygen levels impacts lymphocyte function. *Proc. Natl. Acad. Sci. U. S. A.* 2005, 102 (10), 3756– 9, DOI: 10.1073/pnas.0409910102 [Crossref], Google Scholar
38. Facciabene, A.; Peng, X.; Hagemann, I. S.; Balint, K.; Barchetti, A.; Wang, L. P.; Gimotty, P. A.; Gilks, C. B.; Lal, P.; Zhang, L.; Coukos, G. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. *Nature* 2011, 475 (7355), 226– 30, DOI: 10.1038/nature10169 [Crossref], Google Scholar
39. Bengsch, B.; Johnson, A. L.; Kurachi, M.; Odorizzi, P. M.; Pauken, K. E.; Attanasio, J.; Stelekati, E.; McLane, L. M.; Paley, M. A.; Delgoffe, G. M.; Wherry, E. J. Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an

- Early Driver of CD8(+) T Cell Exhaustion. *Immunity* 2016, 45 (2), 358– 73, DOI: 10.1016/j.immuni.2016.07.008 [Crossref], Google Scholar
40. Patsoukis, N.; Bardhan, K.; Chatterjee, P.; Sari, D.; Liu, B.; Bell, L. N.; Karoly, E. D.; Freeman, G. J.; Petkova, V.; Seth, P.; Li, L.; Boussiotis, V. A. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. *Nat. Commun.* 2015, 6, 6692, DOI: 10.1038/ncomms7692 [Crossref], [PubMed], [CAS], Google Scholar